Efficacy and Safety of Prolonged-Release Lanreotide in Patients With Gastrointestinal Neuroendocrine Tumors and Hormone-Related Symptoms

Wymenga, A.N.M.; Eriksson, Barbro; Salmela, Pasi; Jacobsen, M. B.; Cutsem, E.J.D.G. van; Fiasse, René; Välimäki, Matti; Renstrup, J.; Vries, Elisabeth G.E. de; Öberg, Kjell

doi:10.1200/jco.1999.17.4.1111

Cited by 199 publications

(108 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, the overall response rate (complete plus partial responses) was 37% (95% confidence intervals, 14 -60 %). The median survival time was 15 months (95% Brookmeyer-Crowley confidence interval, [12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27][28], and the median time to progression was 14 months. Estimated curves of overall survival and time to progression are represented, respectively, in Figures 1 and 2.…”

Section: Resultsmentioning

confidence: 99%

“…16 These data provided the rationale for a Phase II study to evaluate the efficacy and toxicity of treatment with somatostatin analogs and prednisone in patients with thymic tumors refractory to chemotherapy. Given the similar affinity profile of octreotide and lanreotide, 17 the comparable effectiveness of lanreotide and regular somatostatin analogs in the treatment of gastrointestinal neuroendocrine tumors, 18 and the advantages of long-acting lanreotide over multiple daily injections of octreotide in terms of patient compliance and costs, 8 patients of 16 were treated with the long-acting somatostatin analog lanreotide, which was the only available long-acting formulation at the time of study beginning.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Somatostatin analogs and prednisone in advanced refractory thymic tumors

Palmieri

Montella

Martignetti

et al. 2002

Cancer

View full text Add to dashboard Cite

BACKGROUND Therapeutic options to cure advanced, recurrent, and metastatic thymic tumors are limited. Evidence of a high uptake of indium‐labeled octreotide (111In‐DTPA‐D‐Phe1‐octreotide) in thymic tumors and the curative application of somatostatin analogs and prednisone in one patient with thymoma and pure red cell aplasia led the authors to start a Phase II study. METHODS Sixteen patients with advanced thymic tumors, unresponsive to conventional chemotherapeutic regimens, were enrolled in the study. The schedule includes administration of somatostatin analog octreotide (1.5 mg/day subcutaneously) associated with prednisone (0.6 mg/kg/day orally for 3 months, 0.2 mg/kg/day orally during follow‐up). In 8 cases, octreotide was replaced by the long‐acting analog lanreotide (30 mg/every 14 days intramuscolarly). Treatment was prolonged until progression of disease was documented. Overall response rate, survival, progression free survival, and toxicity were evaluated. RESULTS The overall response rate among 16 evaluable patients was 37%. One patient (6%) had a complete response, 5 (31%) had a partial response, 6 obtained a stabilization of disease, and 4 progressed during the treatment. After a median follow‐up of 43 months, the median survival was 15 months, and median time to progression was 14 months. Treatment was generally well tolerated with acceptable toxicity: cholelithiasis (1 patient), Grade 2 cushingoid appearance (3 patients), Grade 1 diarrhea (5 patients), Grade 2 hyperglycemia (3 patients). CONCLUSIONS Treatment with somatostatin analogs and prednisone has shown efficacy in patients with recurrent and metastatic malignant thymic tumors refractory to standard therapeutic options. The results obtained are very satisfactory given the lack of effective alternative treatments. Such therapy is not burdened by the same toxicity of chemotherapy; thus, it can be administered to heavily pretreated patients. Somatostatin analogs and prednisone are well tolerated, and the long‐acting analog lanreotide, which requires fewer injections, improves patients' compliance. Cancer 2002;94:1414–20. © 2002 American Cancer Society. DOI 10.1002/cncr.10374

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Somatostatin analogs and prednisone in advanced refractory thymic tumors

Palmieri

Montella

Martignetti

et al. 2002

Cancer

View full text Add to dashboard Cite

show abstract

“…A major disadvantage of this treatment is the need for subcutaneous injections twice (or sometimes thrice) daily. This drawback may be overcome by slowrelease preparations (one intramuscular injection every 2-4 weeks) [52]. In addition to improving symptoms, somatostatin analogues have also been reported to inhibit tumor growth.…”

Section: Octreotide Analoguesmentioning

confidence: 99%

Metastatic Carcinoid Tumors: A Clinical Review

2005

View full text Add to dashboard Cite

Carcinoid tumors are neuroendocrine tumors derived from enterochromaffin cells, which are widely distributed in the body. They can originate from any location in the body, but they are traditionally described as originating from the foregut, midgut, and hindgut. Although the overall incidence of carcinoid tumors appears to have increased in the past decades, the prognosis for patients with metastatic carcinoid tumors has improved during the last decade. Due to longer survival times, complications, such as carcinoid heart disease, and new metastatic patterns, like skin and bone metastases, may become more important features of carcinoid disease. Therapy focused on these complications should be part of the management. Combining new diagnostic and treatment modalities in metastatic carcinoid patients may result in better quality of life and longer survival times. The increasing number of therapeutic options and diagnostic procedures requires a multidisciplinary approach, with decisions made in multidisciplinary meetings focused on "tailor-made" therapy based on patients' specific conditions. Because carcinoid tumors are uncommon, effort should be made to treat these patients in specialized centers and for these centers to join together in multicenter studies. The Oncologist 2005;10:123-131The Oncologist 2005;10:123-131 www.TheOncologist.com

show abstract

“…Octreotide has lengthened survival time in comparison with historical controls and the quality of life has been significantly improved by somatostatin analogues (30).…”

Section: Therapymentioning

confidence: 99%